Navigation Links
Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced
Date:4/17/2008

Center, Morgan Stanley Children's Hospital of New York-Presbyterian, New York- Presbyterian Hospital/Westchester Division and New York-Presbyterian Hospital/The Allen Pavilion. Weill Cornell Medical College is the first U.S. medical college to offer a medical degree overseas and maintains a strong global presence in Austria, Brazil, Haiti, Tanzania, Turkey and Qatar. For more information, visit http://www.nyp.org and http://www.med.cornell.edu.

About Baxter

Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other indications. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

This release includes forward-looking statements concerning GAMMAGARD S/D and GAMMAGARD LIQUID [Immune Globulin Intravenous (IGIV)] relating to clinical trials as well as potential future uses of the products. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: continued review of Phase II data and the limited number of patients studied to date; additional regulatory and other steps required prior to the initiation of the larger Phase III study described in the release; and other risks identified in Baxter's most recent filing on Form 10-K and other Securities and Exchange Commission filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.


'/>"/>
SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014 The steady ... is spreading to previously rep-friendly specialties, according to ... and marketing consulting firm ZS Associates.      ... 200 U.S. pharmaceutical sales teams. The report examines ... meet with the pharmaceutical sales reps who visit ...
(Date:7/22/2014)... 22, 2014 BioDelivery Sciences International, Inc. (BDSI) ... of Directors has appointed Charles J. (Chuck) Bramlage ... members of the Board.  Mr. Bramlage ... in marketing, sales and other commercial functions.  He is ... a development stage company that was recently acquired by ...
(Date:7/22/2014)... 22, 2014  UL (Underwriters Laboratories), a global ... Food and Drug Administration (FDA) has recognized two ... medical devices incorporating lithium or nickel-based batteries. The ... Household and Commercial Batteries, and UL 1642 - ... Consensus standards are standards recognized by the FDA ...
Breaking Medicine Technology:Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2
... , RYE, N.Y., Oct. 14 Curemark, LLC, a drug ... diseases, announced that it has enrolled the first patients in ... The first clinical trial patients have been enrolled at Lake ... trial sites with a total 170 children across the country. ...
... Inc. (Nasdaq: VSCP ), a leading provider of quantitative ... the company,s chief business and financial officer, will be presenting ... Bio Investor Forum in San Francisco, California. Ms. Henderson is ... October 29, 2009 at the Palace Hotel, San Francisco. , ...
Cached Medicine Technology:Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment 2VirtualScopics to Present at the 8th Annual Bio Investor Forum 2
(Date:7/22/2014)... July 22, 2014 The European Bio ... market in Europe with analysis and forecast of revenue. ... grow from around $528.5 million in 2013 to $940.6 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. , http://www.micromarketmonitor.com/market/europe-bio-stimulants-1315565884.html ...
(Date:7/22/2014)... Colorado Springs, CO (PRWEB) July 22, 2014 ... (ASTI), the leader in professional data archiving solutions, ... Cloud-Integrated Storage (CiS) data archiving solution. The ... cloud supporting the company’s focus on compliant data ... enforcement, and more. , The introduction of ...
(Date:7/22/2014)... the University of Murcia have studied the changes ... a personality trait that causes difficulties in inhibiting ... and leads to unplanned actions without considering the ... indicator for predicting the risk of behavioural problems. ... the University of Murcia analyses whether the connectivity ...
(Date:7/22/2014)... There’s an old adage that says ... new improvements and enhancements Global Eyeglasses has made, people ... lasting impressions while having what they need to sport ... , “We are offering new sports clip prescription sunglasses ... Sagar, CEO of Global Eyeglasses . , ...
(Date:7/22/2014)... York, NY (PRWEB) July 22, 2014 ... the Icahn School of Medicine at Mount Sinai have ... associated with the risk of developing schizophrenia, in the ... date, conducted with 80,000 people. The findings, published online ... may underlie schizophrenia, and could lead to new approaches ...
Breaking Medicine News(10 mins):Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 2Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 3Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 4Health News:Children's impulsive behaviour is related to their brain connectivity 2Health News:Global Eyeglasses Adds New Products and Enhances Services 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 3Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 4
... in Afghanistan are increasingly suffering from war–related anxiety and ... ,Ontario’s ombudsman Andre Marin had undertaken a recent ... center for treatment of such traumatized children was caught ... bodies unwilling to take financial responsibilities. ,Mr. ...
... All India Institute of Medical Sciences (AIIMS) Director P. ... a former patient alleging// that the state-run hospital had ... undergoing treatment at its cardiac and neuro center. ... to Venugopal, Mayank Sharma, former senior financial advisor, Arti ...
... scientists have undertaken what is described as the biggest DNA ... mark the biggest single leap in the understanding of how ... to a new wave of tailored therapies and tests to ... ,A coalition of 50 groups, including 24 leading ...
... human interference may destroy much of Sundarbans in India and ... a new UNESCOreport.// ,"Sea-level rise is the greatest ... Asia. A 45 cm rise in global sea levels would ... mangroves," the report warned. ,The report, "Case Studies ...
... may be at far higher risk for eating disorders ... first population-based study of its kind, the// researchers found ... eating disorders. ,Researchers Ilan H. ... the Mailman School of Public Health and principal investigator, ...
... remains the most beneficial proven intervention for ischemic stroke, ... Guidelines for the Early Management of Adults with Ischemic ... intra-arterial administration of clot-busting drugs and mechanical removal of ... guidelines focus on the crucial first hours from the ...
Cached Medicine News:Health News:Collateral Damage-Children Of Canadian Soldiers Suffer 2Health News:Court Issues Notice to Venugopal Over Fund Irregularities 2Health News:UK Scientists to Reveal Genetic Secrets Behind Serious Illnesses 2Health News:Climate Change Threatens Sundarbans and World Heritage Sites 2Health News:Climate Change Threatens Sundarbans and World Heritage Sites 3Health News:Eating Disorders Highly Prevalent Among Gay and Bisexual Men 2Health News:Intravenous Delivery of Clot-busting Drug Still Best Intervention for Ischemic Stroke 2
The only daily cleaner specially formulated with isopropyl alcohol to help dissolve lipids and oil-based make-up from contact lenses....
Clerz Plus helps retain moisture to relieve dryness and removes protein buildup from your lenses while you wear them for longer wear comfort....
Lens Plus rewetting drops for soft contact lenses....
... Renu Multiplus preservative free lubricating ... moisturize your eyes while you're ... gentle preservative free formula is ... be sensitive to preservatives and ...
Medicine Products: